Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

·4 min read

In-person and virtual Presentation: November 10-14th, 2021

ROCHESTER, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Dr. Elizabeth Evans, PhD, Chief Operating Officer and SVP, Discovery and Translational Medicine, will present Poster #434, Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84), at the Society for Immunology of Cancer’s (SITC) 36th Annual Meeting being held from November 12th - 14th in Washington D.C. Please see Presentation details below:

SITC Conference Information

Date:

November 12-14, 2021

Session Title:

Clinical Trials in Progress, Poster Session

Poster #: Title

Poster #434: Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84)

Add to calendar:

https://ir.vaccinex.com/node/8411/ics

Program Link:

https://sitc.sitcancer.org/2021/abstracts/titles/index.php?filter=Keynote+B84

Access:

The Poster will be presented in-person 12:30 -2 and 7 - 8:30 p.m. ET on Saturday, November 13, and on the SITC 2021 virtual meeting platform from 7 a.m. ET on Friday, November 12, 2021, until the virtual meeting platform is closed on January 9, 2022. The Poster will also be available on Vaccinex’s website starting on November 12, 2021, at: https://ir.vaccinex.com/presentations

For more information about the SITC Annual Meeting please refer to the conference website. The in-person program in Washington D.C. will be streamed live on the digital platform.

About Vaccinex, Inc.

Vaccinex, Inc. is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that prevents immune infiltration into tumors and triggers chronic inflammation in the brain, is currently being evaluated in the clinic as a treatment for head & neck cancer and Alzheimer’s disease, with ongoing exploration of potential phase 3 development in Huntington’s disease. The company additionally intends to leverage its proprietary drug discovery platform, ActivMAb®, to create opportunities for future pipeline expansion and strategic collaborations, particularly by exploiting its unique capability to select high value antibodies against important multi-pass membrane receptors including GPCR and ion channels.

Forward Looking Statements

To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Such statements include, but are not limited to, statements about our plans, expectations and objectives with respect to the results and timing of our clinical trials of pepinemab in various indications, the use and potential benefits of pepinemab in Huntington’s and Alzheimer’s disease and other indications, and other statements identified by words such as “may,” “will,” “appears,” “expect,” “planned,” “anticipate,” “estimate,” “intend,” “hypothesis,” “potential,” “suggest”, “advance,” and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab, the impact of the COVID-19 pandemic, and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Securities and Exchange Commission (“SEC”) and the other risks and uncertainties described in the Company’s Form 10-K for year-end December 31, 2020, and subsequent filings with the SEC.

Investor Contact
John Mullaly
LifeSci Advisors, LLC
617-429-3548
jmullaly@lifesciadvisors.com